Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
NCT00805818 is registered in ClinicalTrials.gov with Neuren Pharmaceuticals Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2010
- Completion date
- January 31, 2016
- Enrollment
- 261 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.